G.D. Tollefson

2.1k total citations
76 papers, 1.6k citations indexed

About

G.D. Tollefson is a scholar working on Psychiatry and Mental health, Pharmacology and Cognitive Neuroscience. According to data from OpenAlex, G.D. Tollefson has authored 76 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Psychiatry and Mental health, 26 papers in Pharmacology and 8 papers in Cognitive Neuroscience. Recurrent topics in G.D. Tollefson's work include Schizophrenia research and treatment (36 papers), Treatment of Major Depression (26 papers) and Bipolar Disorder and Treatment (20 papers). G.D. Tollefson is often cited by papers focused on Schizophrenia research and treatment (36 papers), Treatment of Major Depression (26 papers) and Bipolar Disorder and Treatment (20 papers). G.D. Tollefson collaborates with scholars based in United States, Austria and Italy. G.D. Tollefson's co-authors include Charles M. Beasley, Janet H. Potvin, P.V. Tran, R. Tamura, T.M. Sanger, Mauricio Tohen, Mary Anne Dellva, Starr L. Grundy, Jeffery A. Lieberman and Pierre V. Trân and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Cerebral Cortex.

In The Last Decade

G.D. Tollefson

76 papers receiving 1.5k citations

Peers

G.D. Tollefson

PMH

PHARM

PHILO

Pierre V. Trân United States

P. Tran United States

W. Rein France

U. G. Ahlfors Denmark

Caroline Corves Germany

Claudia Leucht Germany

Dan Zimbroff United States

Richard L. Borison United States

Margaretta Nyilas United States

Ibrahim Turkoz United States

Pierre V. Trân United States

G.D. Tollefson

1.5k ×1.3

PMH

616 ×1.4

PHARM

297 ×0.7

304 ×1.3

PHILO

122 ×0.6

Citations per year, relative to G.D. Tollefson G.D. Tollefson (= 1×) peers Pierre V. Trân

Countries citing papers authored by G.D. Tollefson

Since Specialization

Citations

This map shows the geographic impact of G.D. Tollefson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G.D. Tollefson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G.D. Tollefson more than expected).

Fields of papers citing papers by G.D. Tollefson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G.D. Tollefson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G.D. Tollefson. The network helps show where G.D. Tollefson may publish in the future.

Co-authorship network of co-authors of G.D. Tollefson

This figure shows the co-authorship network connecting the top 25 collaborators of G.D. Tollefson. A scholar is included among the top collaborators of G.D. Tollefson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G.D. Tollefson. G.D. Tollefson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lieberman, Jeffrey A., G.D. Tollefson, A. I. Green, et al.. (2009). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404)). American Journal of Psychiatry. 166(8). 12 indexed citations

Thompson, Paul M., George Bartzokis, Kôji Hayashi, et al.. (2008). Time-Lapse Mapping of Cortical Changes in Schizophrenia with Different Treatments. Cerebral Cortex. 19(5). 1107–1123. 83 indexed citations

Faries, Douglas E., John H. Heiligenstein, G.D. Tollefson, & William Z. Potter. (2001). The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials. Journal of Clinical Psychopharmacology. 21(6). 561–568. 60 indexed citations

Dossenbach, Martín, Robert H. Belmaker, Avner Elizur, et al.. (2000). The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clinical Therapeutics. 22(9). 1021–1034. 39 indexed citations

Tollefson, G.D., et al.. (1999). Controlled, Double-Blind Investigation of the Clozapine Discontinuation Symptoms With Conversion to Either Olanzapine or Placebo. Journal of Clinical Psychopharmacology. 19(5). 435–443. 43 indexed citations

Tollefson, G.D.. (1999). Anxious?depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?. Schizophrenia Research. 35. S13–S21. 39 indexed citations

Sanger, T.M., Jeffery A. Lieberman, Mauricio Tohen, et al.. (1999). Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis. American Journal of Psychiatry. 156(1). 79–87. 172 indexed citations

Grainger, David, et al.. (1998). Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders. Schizophrenia Research. 29(1-2). 147–147. 7 indexed citations

Andersen, Stig, Louis Cohen, J. Goldstein, Mauricio Tohen, & G.D. Tollefson. (1998). Sex and neuroendocrine differences in response to treatment with olanzapine: A preliminary analysis. Schizophrenia Research. 29(1-2). 186–187. 4 indexed citations

10.

Trân, Pierre V., et al.. (1997). Extrapyramidal Symptoms and Tolerability of Olanzapine Versus Haloperidol in the Acute Treatment of Schizophrenia. The Journal of Clinical Psychiatry. 58(5). 205–211. 127 indexed citations

11.

Barnas, C., István Bitter, W. W. Fleischhacker, et al.. (1997). Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy. International Journal of Psychiatry in Clinical Practice. 1(sup1). S25–S30. 5 indexed citations

12.

Crawford, A.M., Juan Carlos Gómez, Charles M. Beasley, & G.D. Tollefson. (1997). P.2.015 Olanzapine versus haloperidol: Analysis of schizophrenic patients from the multi-center international trial. European Neuropsychopharmacology. 7. S199–S199. 8 indexed citations

13.

Tollefson, G.D., et al.. (1996). Is there a relationship between baseline and treatment-associated changes in [H]-IMI platelet binding and clinical response in major depression?. Neuropsychopharmacology. 14(1). 47–53. 7 indexed citations

14.

Tollefson, G.D., T.M. Sanger, & Charles M. Beasley. (1996). The course of primary and secondary negative symptoms in a placebo-and comparator-controlled trial of the typical antipsychotic olanzapine. European Neuropsychopharmacology. 6. S4–14. 6 indexed citations

15.

Hamilton, S.H., Marc Hertzman, Barnett S. Meyers, et al.. (1995). Predicting Response to Fluoxetine in Geriatric Patients With Major Depression. Journal of Clinical Psychopharmacology. 15(6). 421–427. 34 indexed citations

16.

Satterlee, W., et al.. (1995). Additional clinical experience with olanzapine, an “atypical” antipsychotic. Schizophrenia Research. 15(1-2). 163–163. 2 indexed citations

17.

Tollefson, G.D.. (1994). A Multicenter Investigation of Fixed-Dose Fluoxetine in the Treatment of Obsessive-compulsive Disorder. Archives of General Psychiatry. 51(7). 559–559. 210 indexed citations

18.

Wood, Andy, G.D. Tollefson, & Martin Birkett. (1993). Pharmacotherapy of obsessive compulsive disorder-experience with fluoxetine. International Clinical Psychopharmacology. 8(4). 301–306. 27 indexed citations

19.

Tollefson, G.D., et al.. (1989). Lymphopenia in primary degenerative dementia. Journal of Psychiatric Research. 23(3-4). 191–199. 16 indexed citations

20.

Garvey, M J, D. Mungas, & G.D. Tollefson. (1984). Hypersomnia in major depressive disorders. Journal of Affective Disorders. 6(3-4). 283–286. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact